Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
Conclusions: These findings suggest that clinicians may be able to use depression rating scale scores early in treatment as a guide to inform treatment optimization. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - August 31, 2017 Category: Psychiatry Tags: Original Contributions Source Type: research
The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.
CONCLUSIONS: Reasons for noncompliance vary by drug class and need to be considered when prescribing antidepressant drugs. Escitalopram, sertraline, and desvenlafaxine perhaps have the most favorable 24-week cost-efficacy profile; tricyclics are poorly tolerated. Rural subjects need to be educated that treatment must be continued even after improvement is established.
PMID: 28827861 [PubMed - in process] (Source: Indian Journal of Psychiatry)
Source: Indian Journal of Psychiatry - August 24, 2017 Category: Psychiatry Tags: Indian J Psychiatry Source Type: research
Desvenlafaxine Appears to Improve Low Energy in Major Depression
Desvenlafaxine appears to improve energy and diminish lassitude in patients with major depressive disorder (MDD), with a significant association between improvements in energy/fatigue and overall functional outcomes, according to areport in theJournal of Psychopharmacology.“Fatigue and lack of energy may have a significant impact on MDD patient functioning, including cognitive functioning at school and at work,” wrote Raymond W. Lamb, M.D., of the University of British Columbia and colleagues. “[I]t is critical for clinicians to treat energy symptoms in patients with depression and to address residual energy symptoms...
Source: Psychiatr News - July 27, 2017 Category: Psychiatry Tags: desvenlafaxine Journal of Psychopharmacology lassitude low energy major depressive disorder Pfizer Raymond Lamb Source Type: research
Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder
This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients. Antidepressant treatment induced inflammasome inhibition was observed by decreased serum levels of IL-1β and IL-18 and decrease of NLRP3 and IL-1β (p17) protein expression. This was also observed under stress-induced depressive behaviour and inflammasome activation in C57Bl/6 mice in vivo. Deleti...
Source: Pharmacological Research - May 3, 2017 Category: Drugs & Pharmacology Source Type: research
[Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
CONCLUSIONS: Although evidence of desvenlafaxine in neuropathic pain is scarce, it presents some interesting pharmacokinetic properties, as it is not substrate or have activity on P-glycoprotein, and have a metabolism which practically does not depend on cytochrome P450 system, which limits the risk of pharmacokinetic interactions and potential problems associated tolerability when administered with drugs that are CYP2D6 moderate or potent inhibitors or other substrates of this isoenzyme. These characteristics make desvenlafaxine a different antidepressant especially useful in some subgroups of patients with chronic pain (...
Source: Revista de Neurologia - February 25, 2017 Category: Neurology Authors: Alcantara-Montero A Tags: Rev Neurol Source Type: research
Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline
Purpose: This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder.
Methods: Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18–40 years,>40 to (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - February 23, 2017 Category: Psychiatry Tags: Original Contributions Source Type: research
Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study
Conclusions:Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders. Further research is needed to identify therapies that enhance the depression and insomnia treatment responses of those with childhood onsets of these two conditions.Citation:Edinger JD, Manber R, Buysse DJ, Krystal AD, Thase ME, Gehrman P, Fairholme CP, Luther J, Wisniewski S. Are patients with childhood onset of insomnia and depression more difficult to treat than are those with adult onse...
Source: Journal of Clinical Sleep Medicine : JCSM - February 15, 2017 Category: Sleep Medicine Source Type: research
Multi-residue determination of micropollutants in Phragmites australis from constructed wetlands using microwave assisted extraction and ultra-high-performance liquid chromatography tandem mass spectrometry.
Abstract
In constructed wetlands micropollutants can be removed from water by phytoremediation. However, micropollutant uptake and metabolism by plants here is poorly understood due to the lack of good analytical approaches. Reported herein is the first methodology developed and validated for the multi-residue determination of 81 micropollutants (pharmaceuticals, personal care products and illicit drugs) in the emergent macrophyte Phragmites australis. The method involved extraction by microwave accelerated extraction (MAE), clean-up using off-line solid phase extraction and analysis by ultra-high-performa...
Source: Analytica Chimica Acta - February 6, 2017 Category: Chemistry Authors: Petrie B, Smith BD, Youdan J, Barden R, Kasprzyk-Hordern B Tags: Anal Chim Acta Source Type: research
Tramadol vs. Everything: 744 Drug Interactions and Counting
BY THOMAS BARROWS, MDA 43-year-old woman presented to our emergency department with complaints of anxiety, intermittent “cramping” in her left hand, and jerking movements of her body that had been going on for five days. She had depression following the death of her son 14 months earlier, for which she was started on Effexor 37.5 mg once daily two weeks earlier.One week before this visit, the patient had back pain and headache, for which she was evaluated at a local emergency department. She had lumbar x-rays showing mild degenerative changes in her spine and a normal head CT scan. The emergency physician...
Source: The Case Files - January 17, 2017 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Development and evaluation ofDesvenlafaxine loaded PLGA-Chitosan nanoparticles for brain delivery
Publication date: Available online 23 December 2016 Source:Saudi Pharmaceutical Journal Author(s): Gui-Feng Tong, Nan Qin, Li-Wei Sun Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Currently, depression affects more than 4 percent of the world’s population. Most of the drugs intended for clinical management of depression augment the availability of neurotransmitters at the synapse by inhibiting their neuronal reuptake. However, the therapeutic efficacy of antidepressants is often compromised as they are unable to reach brain by the conventional r...
Source: Saudi Pharmaceutical Journal - December 23, 2016 Category: Drugs & Pharmacology Source Type: research
Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
Conclusion: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - December 8, 2016 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets
Conclusion: A controllable release pattern of DSV was achieved using Methocel, Maltodextrin and SCMC. The obtained results could be used as a platform to control the release of cationic water soluble drugs that suffer from side effects associated with their initial burst after oral administration. (Source: Saudi Pharmaceutical Journal)
Source: Saudi Pharmaceutical Journal - November 1, 2016 Category: Drugs & Pharmacology Source Type: research
Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects
. (Source: Clinical Toxicology)
Source: Clinical Toxicology - September 12, 2016 Category: Toxicology Authors: J. M. Cooper J. A. Brown R. Cairns G. K. Isbister Source Type: research
A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.
Authors: Liu M, Sun Y, Zhao S, Li Y, Piao R, Yang Y, Gu J
Abstract
O-Desmethylvenlafaxine (desvenlafaxine, ODV) is the active metabolite of venlafaxine, with similar activity and less risk for pharmacokinetic drug interactions compared to its parent compound venlafaxine. The purpose of this study was to design a series of esters of ODV and assess their potential as ODV prodrugs with improved bioavailability and brain uptake. Seven esters were synthesized and pharmacokinetic screening was performed in rats. The monoester formed on the phenolic hydroxyl of ODV (ODVP-1, ODVP-2, ODVP-3 and ODVP-5) could be deg...
Source: Experimental and Therapeutic Medicine - September 3, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research
